^
    Back
    Association details:
    Biomarker:IDH1 R132H
    Cancer:Glioma
    Drug Class:PD-L1 inhibitor +
    IDH1 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    J Clin Invest
    Title:

    Inhibition of 2-Hydroxyglutarate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity in Mice

    Published date:
    12/17/2020
    Excerpt:
    ...we combined D-2HG inhibition/IR/TMZ with anti-PDL1 immune checkpoint-blockade and observed complete tumor regression in 60% of mIDH1 glioma bearing mice...Our preclinical data supports the testing of IDH-R132H inhibitors in combination with IR/TMZ and anti-PDL1 as targeted therapy for mIDH1/mATRX/mTP53 glioma patients.
    Secondary therapy:
    temozolomide
    DOI:
    10.1172/JCI139542